Our Archives section provides access to previously published issues, ensuring a comprehensive resource for researchers, practitioners, and educators.
Explore Past Issues
Volume 1
Issue 2 JULY– DECEMBER 2025
Volume 1 (Issue 2) JULY– DECEMBER 2025 Research Articles
Pharmacokinetic Evaluation and Dose Optimization of a Novel Oral Tyrosine Kinase Inhibitor in Advanced Non-Small Cell Lung Cancer
Vol.1(2); Pages:1-10. Published on July-2025
Abstract
The therapy of advanced non-small cell lung cancer (NSCLC) is still evolving, and novel tyrosine kinase inhibitors (TKIs) have been created. The goal of this Phase I dose-escalation Study was to evaluate the pharmacokinetic (PK) profile, safety and early efficacy of an investigational oral TKI in patients with EGFRpositive NSCLC (n = 24). Three cohorts were used in the study with each one getting an increased dose in a 28- day cycle. PK analysis was done by collecting blood at specific predetermined time points and analyzed by LCMS/MS. The results showed a linear pharmacokinetics and a half-life of 18 hours and no dose-limiting toxicities were observed in the range of therapeutic doses. The incidence of adverse events was highest (Grade 12 nausea and rash). Early tumor response was partial response in 3 patients and stable disease in 11. These results indicate a possibility of further exploration of this TKI at Phase II trials to help in the optimization of dose administration strategies as a means of enhancing therapeutic response in advanced NSCLC.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Novel Liposomal form of Topotecan in Relapsed small Cell Lung cancer: A phase I dose-escalation Study
Vol.1(2); Pages:11-19. Published on July-2025
Abstract
Recurrence of small cell lung cancer (SCLC) following conventional chemotherapy is usually high and few therapeutic alternatives exist. In this dose-escalation Phase I study, the researchers were testing a new nanoliposomal formulation of topotecan, which has greater selectivity in delivering topotecan to tumors with a reduced body burden of toxicity. Twenty-six relapsed SCLC patients were recruited and the maximum tolerated dose (MTD) was determined to be 1.8 mg/m 2. On pharmacokinetic analysis, half-life was prolonged in the plasma and was elevated in the tumour sites as compared to traditional topotecan preparations. Neutropenia appeared to be a dose-limiting toxicity and initial signals of activity included partial responses in 27% and stable disease in 38% of patients. There was also decreased gastrointestinal toxicity as stated by the patients than the standard treatment. These findings validate future Phase II studies and propose that liposomal topotecan has potential to provide useful choice of treatment options in relapsed SCLC.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Assessment of Patient-Reported: Outcomes in Targeted Therapy in Chronic Myeloid Leukemia: A Prospective Observational Study
Vol.1(2); Pages:20-28. Published on July-2025
Abstract
With the introduction of tyrosine kinase inhibitors (TKI)-targeted therapy, chronic myeloid leukemia (CML) treatment became a reality revolution, yet long-term persistence and quality of life (QoL) remain the critical elements toward treatment success. This prospective observational follow-up study used 18 months of followup to assess patient-reported outcomes (PROs) in 210 patients in five European cancer centers on TKI therapy. Fatigue, emotional well-being, burden of treatment and adherence patterns were evaluated using validated questionnaires. The findings showed that 62 percent of patients had severe fatigue and 48 percent claimed to have moderate-intensive burden of treatment. This had to do with every day functions. Nevertheless, compliance was also high (>85%). Multivariate analysis showed that the psychologically oriented support and nurse-led counseling had a positive effect on adherence and QoL. The significance of incorporating the measures of PRO in clinical practice is stressed in this research, and it should be noted that the patient-focused outcomes should be used in treatment planning in management of CML.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Multi-center Phase II study of VEGF Inhibited based Combination Therapy with radiotherapy in Adult Samples with Glioblastoma
Vol.1(2); Pages:29-38. Published on August-2025
Abstract
Glioblastoma (GBM) continues to be an aggressive primary brain tumor with a dismal survival, despite multimodal treatment. In a multicenter phase II study, the role of the combination of VEGF inhibitor (bevacizumab) and standard radiotherapy was examined in 78 patients with newly diagnosed glioblastoma with respect to efficacy. Patients were randomized to take radiotherapy or radiotherapy and bevacizumab. The combination regimen had a meaningful increase in the median progression-free survival (PFS) (11.3 months vs. 7.6 months, p<0.05), but overall survival (OS) benefits were not significant in interim analysis. Peritumoral radiographic edema imagery was low in the combination group, and this led to less corticosteroid usage. Nonsynonymous events such as hypertension and proteinuria, which were aligned to VEGF inhibition but which could be managed by supportive treatment, were also recorded. These findings indicate that the addition of VEGF inhibition to radiotherapy may enhance control of disease progression in glioblastoma, and that the overall survival outcome requires Phase III studies.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Systematic Evaluation and Network-Based Meta-Analysis of Oral SERDs for End-Stage HR-Positive Breast Cancer
Vol.1(2); Pages:39-49. Published on August-2025
Abstract
Selective estrogen receptor degrade (SERDs) are currently observed as candidates of ideal treatment of hormone receptor-positive (HR+) advanced breasts cancer, particularly in patients that do not respond to aromatase inhibitors. The present prospective is a systematic review with network meta-analysis, including 12 randomized controlled clinical trials with 3,142 patients, prescribed oral SERDs, among which there were elacestrant and camizestrant. The comparison was based on the efficacy and tolerability of the analyzed drugs with reference to progression-free survival (PFS) and overall response rate (ORR). The elacestrant was better at PFS over the camizestrant and standard endocrine therapy with the hazard ratios trended in favor of treatment in ESR1-mutant populations. The gastrointestinal and hepatic adverse events were deemed manageable according to safety profiles of all the agents. The analysis of the network gives a comparative analysis of clinical decision-making and shows elacestrant as a future oral SERD option that could be used as a first-line treatment. The results indicate the necessity of a precision-guided application of SERDs and the required long-term outcome trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Issue 1 JANUARY- JUNE 2025
- Volume 1(Issue 1) JANUARY- JUNE 2025
Volume 1(Issue 1) JANUARY- JUNE 2025 Research Articles
Progressive Curriculum Design for Enhancing Readiness in Advanced Pharmacy Practice Experiences
Vol.1(1); Pages:1-8. Published on May-2025
Abstract
Because healthcare is always changing, pharmacy programs now need to develop students who are expert, fast learners and aware of industry trends. In order to link didactic instruction and APPEs, a step-by-step course series was created and included in all the pharmacy curriculum years. The curriculum embeds many important knowledge, skills and attitudes as scaffolded and competence-based modules meant for pre-APPE students. Through using case-based sessions, team exercises, simulated experiences and encouraging reflection, the course series helped students become better prepared, confident and effective during their APPEs.Reviewing student progress throughout several years indicated strong improvements in their preparation, confidence and performance in clinical settings. Students noticed they were more comfortable providing patient care, had improved communication and better understood how different jobs in healthcare work together. Assessments performed by our faculty found that students were making progress in critical thinking and behaving like professionals. By building on core knowledge and aligning education with current practice, the course series has shown how to develop students who are ready for APPEs. Digital health technologies will be added, more activities will be offered outside the core curriculum and student outcomes will be traced as they move into practice after training.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Enhancing Accuracy in E-Prescriptions: Digital Solutions for Customized Medication Compounding
Vol.1(1); Pages:9-15. Published on May-2025
Abstract
Using digital means to send electronic prescriptions has helped reduce typical errors, but preparing compounds is still hard and may result in errors. The report examines how digital measures can make medication instructions given in electronic prescribing systems clearer, more accurate and safer. The paper presents a framework built from real-time validation tools, compound-specific data libraries and interoperability protocols to overcome current problems, user interface challenges and standardization gaps. They help pharmacists understand patient needs better, lower risks of errors and guarantee safer results when treating individual patients.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Advancing Individualized Oncology Care Through Comparative Outcomes Research: Emerging Strategies and Future Directions
Vol.1(1); Pages:16-23. Published on May-2025
Abstract
Oncology is changing tide, as personalized medicine now focuses on designing treatments according to the genetic, molecular and clinical facts of the patient. CER is essential in this way as it objectively compares benefits and risks of different treatments given in real clinics. The result of connecting these systems is being able to identify the best interventions suited to each individual patient. Carrying out CER in personalized oncology has made it easier to organize patient groups, guide healthcare decision-making and reduce wasting of medical resources. Besides, using CER allows adaptive healthcare to include patient-reported responses, evaluate information for time periods and use machine learning and AI. Still, several challenges remain for instance, how different the data is, how different the ways information systems are used and how limited their compatibility with each other. In the future, when CER meets precision oncology, biomarker trials and genomic information, it has the potential to transform cancer treatment. According to future directions, combining different platforms, developing relevant policies and bringing stakeholders together will help everyone access and use CER results in medical care. This way of thinking shows the role CER plays in joining research and personal treatment, always pushing oncology forward.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Evolving Roles in Modern Pharmacy: Functions and Duties of Pharmacists and Pharmacy Support Staff
Vol.1(1); Pages:24-31. Published on May-2025
Abstract
Contemporary pharmacy practice now includes many new tasks, including caring for patients, promoting public health, deciding on medication and working with other health workers. Health professionals rely on pharmacists for their involvement in monitoring drugs, treating chronic illnesses, giving immunizations and watching for side effects. At the same time, pharmacy technicians are now essential members, helping maintain an efficient pharmacy, keep inventory well-managed and prepare medicines correctly. This broadening area of work fits with changes in healthcare that center on making services accessible, safe and focused on results. Also, with electronic prescribing and telepharmacy becoming more common, the way pharmacy professionals function has been transformed. Moving ahead, both pharmacists and pharmacy technicians work to meet new expectations and talents thanks to continual changes in education and laws. In this work, we examine how these experts’ roles have shifted in the modern pharmacy environment and highlight the benefits of flexible models, ongoing professional growth and collaborative ways for reaching the best results for patients.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Benzydamine in Managing Chemoradiotherapy-Related Oral Mucositis: A Preventive and Therapeutic Approach
Vol.1(1); Pages:32-38. Published on May-2025
Abstract
Contemporary pharmacy practice now includes many new tasks, including caring for patients, promoting public health, deciding on medication and working with other health workers. Health professionals rely on pharmacists for their involvement in monitoring drugs, treating chronic illnesses, giving immunizations and watching for side effects. At the same time, pharmacy technicians are now essential members, helping maintain an efficient pharmacy, keep inventory well-managed and prepare medicines correctly. This broadening area of work fits with changes in healthcare that center on making services accessible, safe and focused on results. Also, with electronic prescribing and telepharmacy becoming more common, the way pharmacy professionals function has been transformed. Moving ahead, both pharmacists and pharmacy technicians work to meet new expectations and talents thanks to continual changes in education and laws. In this work, we examine how these experts’ roles have shifted in the modern pharmacy environment and highlight the benefits of flexible models, ongoing professional growth and collaborative ways for reaching the best results for patients.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
